



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health/ NCI
9609 Medical Center Drive, Suite 530
Rockville, MD 20852
Office (240) 276-5530
Facsimile (240) 276-5504

DATE: June 18, 2019

RE: KEI Comments in Regard to 84 FR 23798, "*Prospective Grant of Exclusive Patent License: The Development and Use of a Therapeutic STAT3 Inhibitor, GLG-302, in All Proliferative Diseases, Where STAT3 Is Present*" notice – Prospective Exclusive License Grant to GLG Pharma LLC.

Dear Mr. Love, Dr. Ress, and Mr. Abinader

Thank you for providing KEI comments to the recent Federal Register Notice referenced above regarding the National Cancer Institute's proposed intent to grant an exclusive license to GLG Pharma LLC. The notice period provides an opportunity for public comment and possible objection to the proposed license. We consider all comments prior to negotiating the proposed license. We will give your comments and suggestions serious consideration.

Best regards,

Sidra Ahsan, Ph.D.
Licensing and Patenting Manager
Technology Transfer Center
National Cancer Institute/NIH
9609 Medical Center Drive, RM 1-E530 MSC 9702
Rockville, MD 20852
Phone: 240-276-5530
Email: ahsans@mail.nih.gov